This month, biosimilar developer Sandoz filed suit against Amgen, asking the United States district court for the Northern District of California for a declaratory judgment of patent noninfringement and invalidity.
This month, biosimilar developer Sandoz filed suit against Amgen, asking the United States district court for the Northern District of California for a declaratory judgment of patent noninfringement and invalidity.
The suit relates to Amgen’s US patent number 9,643,997 (the ’997 patent), which relates to processes for purifying proteins and capturing those proteins by a separation matrix. Sandoz and Amgen already litigated a similar patent, US patent number 8,940,878 (the ’878 patent), in relationship to Sandoz’s manufacturing process for its filgrastim biosimilar, Zarxio, and its pegfilgrastim biosimilar, which is pending an FDA decision and which is approved in the European Union under the trade name Ziextenzo. In the prior case, in 2017, the court granted a summary judgment of noninfringement of the ’878 patent.
According to the new complaint, the ’997 patent and the ’878 patent are in the same patent family and are similar or even identical in many respects. The only differences between the patents, says Sandoz’s complaint, are ones that do not relate to the grounds on which Sandoz successfully gained a summary judgment of noninfringement in the prior litigation.
The complaint indicates that Sandoz discovered the similarity between the 2 patents and asked Amgen in 2017 to litigate claims related to the ’997 patent together with those of the ’878 patent. However, Sandoz says that Amgen did not amend its litigation to include the ’997 patent and has now allowed 20 months to elapse without taking action on the matter.
Despite not yet having alleged infringement of the ’997 patent, “Amgen has not disavowed the intention to seek a preliminary injunction,” said the Sandoz complaint, adding that the suit seeks to “…ensure that any issues with respect to the ’997 patent, including any preliminary injunction motion, are resolved promptly, efficiently, and well in advance of the launch of Sandoz’s pegfilgrastim product.”
Sandoz gave Amgen its 180-day notice that it plans to begin commercially marketing the biosimilar pegfilgrastim in the United States at its earliest opportunity.
The Sandoz pegfilgrastim biosimilar received a complete response letter from the FDA in July 2016, after which Sandoz worked with the agency to address its concerns. Sandoz agreed with the FDA to undertake an additional study to resolve the agency’s outstanding questions with an eye toward a 2019 resubmission of its Biologics License Application.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.